Novo Nordisk 2018Q4

Novo Nordisk has released their annual report. Positive growth was driven primarily by Ozempic┬« in the US, Saxenda┬«, Tresiba┬« and Victoza┬«, whereas negative growth was driven by primarily Levemir┬« in the US. The mentioned drugs and the trailing twelve month (TTM) sales of diabetes and obesity drugs are summarised below. Name Drug Type Injection Therapy …